[ad_1]
Medford, MA, March 19, 2024–(BUSINESS WIRE)–Solu Therapeutics is a biotechnology company focused on developing therapeutics that use CyTaC to eliminate disease-causing cells.TM (Cytotoxic Targeting Chimera) Platform today announced the appointment of Michael I. Boletti, Ph.D., as Chief Business Officer (CBO).
Dr. Boletti brings more than 15 years of biotechnology leadership experience to Solu, including an extensive track record of building companies and transactions across a variety of therapeutic indications. As CBO, he will lead Solu’s business development strategy, strategic financing and partnership management activities.
“Solu’s innovative approach to elucidating previously inaccessible targets using the CyTaC platform presents a new way to efficiently eliminate disease-causing cells across a wide range of indications,” said Boretti. the doctor commented. “I’m excited to join the passionate Solu team as we advance the development of new medicines that positively impact patients’ lives.”
Dr. Boletti most recently served as CBO for Celsius Therapeutics, where he was responsible for business development and other duties. Previous strategic biopharmaceutical leadership positions include Vice President of Business Development for Epizyme and Vice President of Corporate Development and Alliance Management for Aveo Oncology. Dr. Boletti began his consulting career at LEK Life Science after receiving his Ph.D. He received his PhD in bioengineering from the University of Pennsylvania.
“We are pleased to welcome Mike to Solu’s leadership team. He will be instrumental in driving our strategic alliances and financing efforts as we continue to develop the CyTaC platform and advance our pipeline of next-generation therapeutics.” ‘s capabilities will be an asset during this critical growth period in “oncology and immune-mediated diseases,” said Philip J. Vickers, Ph.D., president and chief executive officer of Solu Therapeutics. “Mike is a skilled and collaborative corporate strategist who works to maximize the value and impact of our platform, making him an ideal addition to his team at Solu Leadership.”
About Sol Therapeutics
Solu Therapeutics is a biotechnology company focused on developing treatments that eliminate disease-causing cells in cancer and immunology. Exclusively licensed from GSK, the proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates target cellular targets such as GPCRs and ion channels that are difficult to target with traditional biological and small molecule approaches. Unleash surface targets. The CyTaC platform provides the ability to develop next-generation drugs that harness the power of biologics with a vast target binding space for small molecules.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240319208421/ja/
contact address
media
Karen Sharma
McDougall Advisor
ksharma@macdougall.bio
[ad_2]
Source link
